Thanks to our close relationship with vendors and manufacturers, we have the unique capability to find niche products and hard to find medicines. You can rely on us for getting the newest approved products on the market and those not yet available in some countries. Our range of products is so wide, you won’t need to look for other suppliers.
with a wide clients’ base consisting of hospitals, private clinics, pharmacies and distributors, we have developed a deep knowledge of what the needs, constraints and priorities are for each of our clients. That is why we understand your urgency and we can fully meet your demands with the highest standards of service.
Our stringent operating procedures guarantee every step of handling, storage and distribution of all medicinal products.
When you contact us at Elixi, you know you are getting the best customer service: our dedicated people will offer you quick responses, personalised approach and bespoke solutions. Our approach is not to follow only standard procedures but to take care of every specific detail, of each request and individual issues.
The US FDA has approved the first interchangeable biosimilar product to treat certain inflammatory diseases. Cyltezo (adalimumab-adbm), originally approved in
EMA has recommended granting a marketing authorisation in the European Union (EU) for Trodelvy (sacituzumab govitecan), a first-in-class medicine to treat adult
The FDA has approved Byooviz (ranibizumab-nuna) as the first biosimilar to Lucentis (ranibizumab injection) for the treatment of several eye
The FDA has approved a nasal antihistamine for nonprescription use through a process called a partial prescription to nonprescription switch.
Aduhelm (aducanumab) has been approved by the FDA for the treatment of Alzheimer’s, a debilitating disease affecting 6.2 million Americans.
Wegovy (semaglutide) injection (2.4 mg once weekly) has been approved by the FDA for chronic weight management in adults with
Vicolo Oldelli 1
6830 Chiasso / Switzerland
Email info@elixi-int.com
Phone/Fax +41 91 6822040
